Xencor stock rises after promising cancer drug shows efficacy in trial
PositiveFinancial Markets

Xencor's stock has seen a significant rise following promising results from a clinical trial of its new cancer drug, which has shown efficacy in treating patients. This development is crucial as it not only boosts investor confidence but also highlights the potential for innovative treatments in the fight against cancer, offering hope to many who are affected by this disease.
— Curated by the World Pulse Now AI Editorial System










